Company: SXTPW
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-014334
Chunk: 327

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-02-14
Form: S-1
Chunk 327
---
 February 8, 2027. II-4 The warrants described above were deemed exempt from registration in reliance on Section 4(a)(2) of the Securities Act or Regulation D promulgated thereunder in that the issuance of securities were made to an accredited investor and did not involve a public offering. The recipients of such securities represented its intention to acquire the securities for investment purposes only and not with a view to or for sale in connection with any distribution thereof. (c) Option Grants. On July 11, 2023, we granted a total of 3,148 fully vested, non-qualified options to purchase shares of common stock at a per share exercise price of $63.60 to the following directors and in the amounts listed: (i) Stephen Toovey (787 common stock options), (ii) Charles Allen (787 common stock options), (iii) Paul Field (787 common stock options) and (iv) Cheryl Xu (787 common stock options). On July 16, 2024, the effective date of shareholder approval to increase the number of shares authorized under the 2022 Plan, we granted a total of 2,516 fully vested, non-qualified options to purchase shares of common stock at a per share exercise price of $63.60 to the following directors and in the amounts listed: (i) Stephen Toovey (629 common stock options), (ii) Charles Allen (629 common stock options), (iii) Paul Field (629 common stock options) and (iv) Cheryl Xu (629 common stock options). On July 16, 2024, the effective date of shareholder approval to increase the number of shares authorized under the 2022 Plan, we granted a total of 61,667 options to purchase shares of common stock at a per share exercise price of $12.00 to Geoff Dow, our Chief Executive Officer, (25,000 common stock options), Tyrone Miller, our Chief Financial Officer (20,000 common stock options), and Bryan Smith, an external consultant, (16,667 common stock options). These options vest in five equal tranches on the last date of each fiscal year, with the first vesting date being December 31, 2024. On September 26, 2024, we granted 20,834 options to purchase shares of common stock at a per share exercise price of $1.37 to Kristen Landon, our Chief Commercial Officer, which vest in five equal tranches on the last date of each fiscal